SCHEMBL4419259

SCHEMBL4419259

CC(C)(C)c1ccc(S(=O)(=O)N2CC3C(CNc4ccc(N5CCOCC5)c(F)c4)C3C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.53
MAOA P21397 1/20 0.53
HSD11B1 P28845 5/20 0.46
ALDH1A1 P00352 3/20 0.42
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 1/20 0.41
LDHA P00338 1/20 0.40
LDHB P07195 1/20 0.40
HTT P42858 1/20 0.39
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4422647 0.92 MAOB (0.45) MAOBMAOAHSD11B1ALDH1A1HPGD
SCHEMBL4414455 0.92 EPHX2 (0.48) MAOBMAOAALDH1A1HPGDNPSR1
SCHEMBL4417872 0.90 ALDH1A1 (0.45) MAOBALDH1A1HPGDNPSR1KMT2A
SCHEMBL4419968 0.90 L3MBTL1 (0.46) MAOBALDH1A1HPGDNPSR1KMT2A
SCHEMBL4423693 0.89 MAPK1 (0.44) MAOBMAOAALDH1A1HPGDNPSR1
SCHEMBL4425190 0.88 MEN1 (0.46) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL4414933 0.88 KMT2A (0.43) MAOBMAOAALDH1A1HPGDNPSR1
SCHEMBL4413584 0.88 ALDH1A1 (0.48) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL4417782 0.88 MAPT (0.45) MAOBMAOAALDH1A1HPGDNPSR1
SCHEMBL4415523 0.88 L3MBTL1 (0.44) ALDH1A1HPGDNPSR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MAOB 307/4885MAOA 726/4885HSD11B1 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.